Study: NCT06782958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 50mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (50 mg) ,administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (50 mg) ,administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (100 mg) , administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (100 mg) , administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (100 mg) , administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (150 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 150 mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (150 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (150 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg FHND1002（fasting）
Description: Participants will receive a daily oral dose of FHND1002 granules (200 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 200 mg FHND1002（fasting）
Description: Participants will receive a daily oral dose of FHND1002 granules (200 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg FHND1002（fasting）
Description: Participants will receive a daily oral dose of FHND1002 granules (200 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 250mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (250 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (250 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 200mg FHND1002(postprandial)
Description: Participants will receive a one-time dose (200 mg) under postprandial conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg FHND1002(postprandial)
Description: Participants will receive a one-time dose (200 mg) under postprandial conditions